|
|
|
|
|
Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00025662 |
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and melphalan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells that have been treated in the laboratory after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and removing the T cells from the donor cells before transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well fludarabine, melphalan, and donor peripheral stem cell transplant followed by cyclosporin work in treating older patients with hematologic cancer.
Condition | Intervention | Phase |
Leukemia Lymphoma Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases |
Drug: cyclosporine Drug: fludarabine phosphate Drug: melphalan Drug: therapeutic allogeneic lymphocytes Procedure: in vitro-treated peripheral blood stem cell transplantation |
Phase II |
MedlinePlus related topics: | Cancer Leukemia, Adult Acute Leukemia, Adult Chronic Lymphoma |
ChemIDplus related topics: | Melphalan Fludarabine Fludarabine monophosphate Cyclosporine Cyclosporin Melphalan hydrochloride Sarcolysin Interleukin-2 |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | Ex Vivo Selective Depletion of Alloreactive Donor T Lymphocytes Utilizing RFT5-SMPT-dgA, a Specific Anti-Interleukin-2 Receptor Immunotoxin: Reducing Graft-Versus-Host Disease Risk Associated With HLA-Matched, Nonmyeloablative, Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies in Older Adults |
Estimated Enrollment: | 28 |
Study Start Date: | May 2001 |
OBJECTIVES:
OUTLINE: Patients receive fludarabine IV over 30 minutes on days -7 to -3 and melphalan IV on day -2. Patients undergo infusion of allogeneic T-cell-depleted and CD34-enriched peripheral blood stem cells and selectively depleted lymphocytes on day 0.
Patients also receive cyclosporine orally or IV on days -4 to 100 as graft-versus-host disease prophylaxis. Patients may receive unmanipulated or selectively depleted donor lymphocytes on day 100.
Patients are followed every 2 months for 1 year, every 3 months for 2 years, and then every 6 months for 2 years.
PROJECTED ACCRUAL: A total of 15-28 patients will be accrued for this study.
Ages Eligible for Study: | 50 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
One of the following diagnoses:
Acute lymphoblastic leukemia (ALL) in complete remission (CR) or partial remission (PR)
Acute myelogenous leukemia (AML) in first CR or PR, including AML secondary to prior chemotherapy or prior hematologic disease (e.g., myelodysplastic syndrome [MDS] or myeloproliferative disorder) or AML in second or subsequent CR
MDS, including any of the following:
Chronic lymphoblastic leukemia or prolymphocytic leukemia
Intermediate- or high-grade non-Hodgkin's lymphoma (NHL)
Hodgkin's lymphoma meeting one of the following criteria:
Low-grade follicular or small lymphocytic lymphoma meeting one of the following criteria:
Must have an HLA-identical family donor
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Pulmonary:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
United States, Maryland | |||||
NIH - Warren Grant Magnuson Clinical Center | |||||
Bethesda, Maryland, United States, 20892-1182 |
Study Chair: | Austin J. Barrett, MD, FRCP | NHLBI - Bone Marrow Transplantation Unit |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000068983, NHLBI-01-H-0162, NCI-5783 |
First Received: | October 11, 2001 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00025662 |
Health Authority: | United States: Federal Government |
|
|
|
|
|
|